Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Shots:

  • Innovent to receive milestones for development and commercialization along with royalties on net sales of the therapy in the licensed territory. Etana is committed to launch Byvasda in Indonesia
  • The collaboration will enable Byvsada to penetrate into a Southeast Asian market and allow Innovent to bolster its presence globally
  • In Jan’2020, Innovent signed an out-license agreement with Coherus to commercialize the biosimilar in the US & Canada

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Innovent Bio

The post Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia first appeared on PharmaShots.